Goldman Sachs Group Inc Cyteir Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.99 - $4.05 $25,410 - $51,714	-12,769 Reduced 52.25%	11,670 $22,000
Q3 2022 Nov 10, 2022	SELL	$1.99 - $4.05 $25,410 - $51,714	-12,769 Reduced 52.25%	11,670 $0
Q2 2022 May 14, 2024	BUY	$1.62 - $4.4 $39,591 - $107,531	24,439 New	24,439 $73,000
Q2 2022 Aug 15, 2022	BUY	$1.62 - $4.4 $17,240 - $46,824	10,642 Added 77.13%	24,439 $73,000
Q1 2022 May 16, 2022	BUY	$3.39 - $10.51 $5,627 - $17,446	1,660 Added 13.68%	13,797 $52,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $119,306 - $233,151	12,137 New	12,137 $138,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.